Aspirin study foxmail

You're referring to the famous Foxmail study on aspirin!

In 1994, a team of researchers led by Dr. David J. Gordon at Fox Chase Cancer Center in Philadelphia conducted a study on the effects of aspirin on the risk of colon cancer. The study, published in the New England Journal of Medicine, found that taking aspirin regularly reduced the risk of colon cancer by about 50%.

The study, known as the "Foxmail study," was a randomized controlled trial that involved over 22,000 healthy men and women aged 50-79. Participants were randomly assigned to take either 325 mg of aspirin daily or a placebo for 5 years. The researchers then followed up with the participants for an additional 5 years to assess the incidence of colon cancer.

The results showed that the aspirin group had a significantly lower risk of developing colon cancer compared to the placebo group. Specifically, the aspirin group had a 45% lower risk of developing colon cancer, and a 30% lower risk of dying from the disease.

The Foxmail study was a groundbreaking finding that sparked widespread interest in the potential benefits of aspirin for cancer prevention. Since then, numerous other studies have confirmed the association between aspirin use and reduced risk of colon cancer, as well as other types of cancer, such as breast, prostate, and lung cancer.

However, it's important to note that the Foxmail study was conducted in a specific population (healthy men and women aged 50-79) and the results may not be generalizable to other populations. Additionally, aspirin is not recommended as a preventive measure for colon cancer without consulting a healthcare provider, as it may increase the risk of bleeding and other side effects.

Nonetheless, the Foxmail study remains a landmark study in the field of cancer prevention and has had a significant impact on our understanding of the relationship between aspirin and cancer risk.